Michael Kauffman, M.D., Ph.D., has served as a member of our Board of Directors since December 2016. Dr. Kauffman currently serves as Chief Executive Officer and President of Nereid Therapeutics. Prior to that, Dr. Kauffman co-founded Karyopharm Therapeutics, Inc. in 2008 and served as its Chief Executive Officer from January 2011 through May 2021 and as a member of its Board of Directors from 2008. Dr. Kauffman also served as Chief Medical Officer from December 2012 to December 2013. Prior to that, Dr. Kauffman served as the Chief Medical Officer at Onyx Pharmaceuticals, Inc., and as Chief Medical Officer of Proteolix, Inc., prior to his position of Chairman of the Board. Dr. Kauffman also served as President and Chief Executive Officer of both Epix Pharmaceuticals, Inc. and Predix Pharmaceuticals, Inc., and was an operating partner at Bessemer Venture Partners. Dr. Kauffman also held several senior positions at Millennium Pharmaceuticals, Inc. and Biogen Idec, Inc. Dr. Kauffman has served on the board of directors of Verastem Inc., a publicly held biopharmaceutical company, since November 2012. Dr. Kauffman received his B.A. in Biochemistry from Amherst College and his M.D. and Ph.D. in Biochemistry, Cellular and Molecular Biology degrees from Johns Hopkins Medical School. Dr. Kauffman completed his residency in Internal Medicine at Beth Israel Deaconess Hospital and was a fellow in Rheumatology at Massachusetts General Hospital; he is Board Certified in Internal Medicine.